| Literature DB >> 27716659 |
Luís F J R Miranda1, Karina B Gomes2, Pedro A L Tito3, Josianne N Silveira2, Gerson A Pianetti2, Ricardo M D Byrro2, Patrícia R H Peles4, Fernando H Pereira1, Thiago R Santos5, Arthur G Assini2, Valéria V Ribeiro2, Edgar N Moraes1,6, Paulo Caramelli1,4.
Abstract
The clinical response to donepezil in patients with mild and moderate dementia was investigated in relation to the drug plasma concentration and APOE and CYP2D6 polymorphisms. In a prospective naturalistic observational study, 42 patients with Alzheimer's disease (AD) and AD with cerebrovascular disease who took donepezil (10 mg) for 12 months were evaluated. Their DNA was genotyped, and the donepezil plasma concentrations were measured after 3, 6, and 12 months. Good responders scored ≥-1 on the Mini-Mental State Examination at 12 months in comparison to the baseline score. The study results indicated the good response pattern was influenced by the concentration of donepezil, but not by APOE and CYP2D6 polymorphisms.Entities:
Keywords: APOE; Alzheimer’s disease; CYP2D6; donepezil; genetics; naturalistic study
Mesh：
Substances：
Year: 2017 PMID： 27716659 DOI： 10.3233/JAD-160164
Source DB: PubMed Journal: J Alzheimers Dis ISSN： 1387-2877 Impact factor: 4.472